Figure 7. EG7-Fc tumors are functional both as a prophylactic inactivated cell vaccine and as a therapeutic live cell vaccine. (A) Groups of 5 mice were administered either EG7-EV or EG7‐Fc cells (5 × 105, mitomycin C treated) as vaccines in the left flanks. After 14 d, both groups received unmanipulated live EG7 cells subcutaneously in the right flank. Mice were followed longitudinally and tumor volumes were assessed by using Vernier’s Calipers. (B‒C) Mice were injected with 5 × 105 live unmanipulated EG7 tumors into the left flank. Mice (n = 15 each group) were then treated with 5 × 105 of live tumor (EG7-EV or EG7-Fc) or vehicle in the right flank on day 1, 2, 4, and 10. Mice treated with EG7-Fc expressing tumors had significantly smaller primary tumors in the left flank by day 21 than animals treated with vehicle (p < 0.05, independent t-test) while animals treated with EG7-EV did not show any diminution in tumor size compared with the vehicle. Panel (B) shows the raw data, panel C shows mean tumor volume of each group. The data are representative of two independent experiments.